| Latest | F'cast | |
|---|---|---|
| Div Yield | 1.9% | |
| Div Cover | 2.1 | |
| Op Mrgn | 23.4% | |
| ROCE | 59.5% |
| Latest | F'cast | |
|---|---|---|
| P/E | 26.1 | |
| PEG | 0.6 | |
| Pr/Revenue | 3.7 | |
| Pr/Book | 4.5 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 8.6% | |
| PBT | 42.7% | |
| EPS | 45.4% | |
| DPS | 3.2% |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 37,417.00 | (265.00) | 8.00¢ | 1,429.6 | n/a | -97% | 287.00¢ | 2.5% |
| 31-Dec-22 | 44,351.00 | 2,501.00 | 212.00¢ | 70.0 | 0.0 | +2,550% | 290.00¢ | 2.0% |
| 31-Dec-23 | 45,811.00 | 6,899.00 | 726.00¢ | 19.3 | 0.1 | +242% | 290.00¢ | 2.1% |
| 31-Dec-24 | 54,073.00 | 8,691.00 | 454.00¢ | 30.4 | n/a | -38% | 310.00¢ | 2.2% |
| 31-Dec-25 | 58,739.00 | 12,402.00 | 660.00¢ | 27.6 | 0.6 | +45% | 320.00¢ | 1.8% |
| Director/PDMR Shareholding | 22-Dec-2025 | 11:00 | RNS |
| Enhertu granted BTD for post-neoadjuvant early BC | 22-Dec-2025 | 07:30 | RNS |
| Update on LATIFY Phase III trial of ceralasertib | 22-Dec-2025 | 07:00 | RNS |
| Director/PDMR Shareholding | 22-Dec-2025 | ShareCast |
| Enhertu granted BTD for post-neoadjuvant early BC | 22-Dec-2025 | ShareCast |
| Update on LATIFY Phase III trial of ceralasertib | 22-Dec-2025 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 11,920.00p |
| Change Today | -2.76p |
| % Change | -2.24 % |
| 52 Week High | 15,286.00 |
| 52 Week Low | 11,456.00 |
| Volume | 6,753 |
| Shares Issued | 1,264.16m |
| Market Cap | £150,688m |
| Time | Volume / Share Price |
| 08:02 | 74 @ 11,920.00p |
| 08:02 | 20 @ 11,926.00p |
| 08:02 | 6 @ 11,922.00p |
| 08:02 | 29 @ 11,922.00p |
| 08:02 | 50 @ 11,918.00p |
You are here: research